<DOC>
	<DOCNO>NCT00779545</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind within dose level , parallel group comparison mometasone furoate nasal spray subject perennial allergic rhinitis examine minimal effective dose , recommend dose , dose regimen .</brief_summary>
	<brief_title>A Study Mometasone Furoate Nasal Spray Perennial Allergic Rhinitis ( Study P03748 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<criteria>Patients mongoloid race reside Japan satisfy follow criterion : Patients symptoms allergic rhinitis moderate severe degree , accord classification severity guideline treatment nasal allergy ( partial revision ) well score least 4 score 4 nasal symptom , time obtain informed consent pretreatment observation period . Patients skin specific IgE test positive cytological examination eosinophil nasal discharge nasal challenge test positive . Outpatients age 16 year time obtain informed consent . Male female . Patients informed consent obtain writing ( informed consent obtain patient 's legally acceptable representative , 20 year ) . Patients daily complete nasal allergy diary . Patients meet follow exclusion criterion include present study : Patients complication tuberculous disease lower respiratory tract infection , patient complication acute upper respiratory tract inflammation acute laryngopharyngitis ( sub ) investigator considers necessary treat time enrollment treatment . Patients complication infection systemic mycosis effective antibiotic available . Patients unhealed nasal septum ulcer , nasal surgery , nasal trauma . Patients hypersensitivity steroid mometasone furoate . Patients pregnant , nursing , possibly pregnant , desire become pregnant study period . Patients severe hepatic , renal , cardiac disorder , blood disease , diabetes , hypertension , serious complication , suffer problem systemic condition . Patients pollen overlap allergen study plan implement pollen release season . Patients complication vasomotor rhinitis eosinophilic rhinitis . Patients complication nose disease may interfere efficacy evaluation investigational product . Patients complicate acute upper respiratory tract inflammation 7day observation period prior enrollment may affect nasal symptom . Patients previously receive mometasone furoate nasal spray . Patients participate clinical trial investigational product ( ) within 4 month obtain informed consent participate present . Patients prior medication effective allergic rhinitis withdrawn long enough initiation treatment investigational product precede medication withdrawn . Patients treat specific desensitization therapy nonspecific allassotherapy therapy withdrawn within 3 month obtain informed consent ( except patient receive maintenance therapy present therapy begin 6 month obtain informed consent ) . Other patient ( sub ) investigator judge inappropriate participation present study .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>